Related Experiment Videos
Biosimilars for Rheumatoid Arthritis: Don't Count Them Out Quite Yet
Managed Care (Langhorne, Pa.)
|January 26, 2018
Abstract:
Because physicians and health plan members both value choice, the current weak market for Inflectra and Renflexis could be a passing phase.
Keywords:
Viewpoint